Yahoo Finance

Operations: The company's revenue is derived from its operations in Turkey, specifically TRY9.36 billion from holding activities and TRY1.10 billion from marine activities both domestically and internationally.

Market Cap: TRY3.97B

GSD Holding A.S., with a market cap of TRY3.97 billion, has shown recent financial improvement, reporting a net income of TRY82.84 million in Q3 2024 compared to a significant loss the previous year. Despite being unprofitable over the past five years with declining earnings by 53.1% annually, it maintains strong liquidity, as short-term assets exceed both short- and long-term liabilities significantly. The company's cash runway is robust for over three years based on current free cash flow trends, although its dividend sustainability remains questionable due to insufficient coverage by earnings or free cash flows.

• Click to explore a detailed breakdown of our findings in GSD Holding's financial health report.

• Examine GSD Holding's past performance report to understand how it has performed in prior years.

Medivir

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Medivir AB (publ) is a pharmaceutical company that develops and commercializes cancer treatments in the Nordic region, Europe, and internationally, with a market cap of SEK356.69 million.

Operations: The company's revenue is derived entirely from its Pharmaceuticals segment, amounting to SEK7.03 million.

Market Cap: SEK356.69M

Medivir AB, with a market cap of SEK356.69 million, is navigating its pre-revenue phase in the biotech sector by focusing on innovative cancer treatments. The company recently announced the US IND approval for a phase 2b study combining fostrox and Lenvima for advanced HCC, following promising outcomes from earlier trials showing extended treatment benefits and improved patient outcomes. Despite being unprofitable and having less than a year of cash runway, Medivir maintains strong short-term asset coverage over liabilities and remains debt-free. However, shareholder dilution has occurred as shares outstanding increased by 7.3% last year.

• Click here to discover the nuances of Medivir with our detailed analytical financial health report.

• Review our growth performance report to gain insights into Medivir's future.

Summing It All Up

• Reveal the 5,810 hidden gems among our Penny Stocks screener with a single click here.

• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.

• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Jump on the AI train with fast growing tech companies forging a new era of innovation.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include DB:02P IBSE:GSDHO and OM:MVIR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com